{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:31:03Z","timestamp":1790487063171,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1053\/j.seminhematol.2010.06.006","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T05:04:19Z","timestamp":1285736659000},"page":"362-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Elusive Chronic Myeloid Leukemia Stem Cell: Does It Matter and How Do We Eliminate It?"],"prefix":"10.1053","volume":"47","author":[{"given":"Bing Z.","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan H.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.06.006_bib1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","article-title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL","volume":"11","author":"Nardi","year":"2004","journal-title":"Curr Opin Hematol."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib5","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib6","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.critrevonc.2005.06.007","article-title":"Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)","volume":"57","author":"Walz","year":"2006","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib9","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib10","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib11","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2004-08-3373","article-title":"Punish the parent not the progeny","volume":"105","author":"Elrick","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib12","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","article-title":"Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli","volume":"19","author":"Holtz","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hon.813","article-title":"Therapeutic targets in chronic myeloid leukaemia","volume":"25","author":"Heaney","year":"2007","journal-title":"Hematol Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib14","series-title":"Chronic myeloid leukaemia: biology and treatment","first-page":"73","article-title":"Progenitor cell dynamics","author":"Eaves","year":"2001"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10428190500272507","article-title":"Detection of molecular targets on the surface of CD34+\/CD38-- stem cells in various myeloid malignancies","volume":"47","author":"Florian","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib17","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","article-title":"Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib","volume":"114","author":"Lemoli","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib19","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.0900189106","article-title":"Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation","volume":"106","author":"Abrahamsson","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib22","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"19;","author":"Ito","year":"2008","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib23","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib24","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2009-06-228130","article-title":"PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice","volume":"115","author":"Peng","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib27","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.4161\/cc.8.21.9852","article-title":"The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia","volume":"8","author":"Chen","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib28","first-page":"1730","article-title":"A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors","volume":"62","author":"Feuring-Buske","year":"2002","journal-title":"Cancer Res."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.leu.2402744","article-title":"Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice","volume":"17","author":"Black","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib30","doi-asserted-by":"crossref","unstructured":"Frolova O, Wang R-Y, Korchin B, et al. Targeting IL3 receptor in chronic myeloid leukemia [abstract]. American Society of Hematology meeting. December 5-8, 2009; New Orleans, LA.","DOI":"10.1182\/blood.V114.22.2172.2172"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib31","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J.Clin.Oncol."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.stem.2009.03.015","article-title":"Hedgehog signaling is dispensable for adult hematopoietic stem cell function","volume":"4","author":"Gao","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.stem.2009.03.016","article-title":"Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis","volume":"4","author":"Hofmann","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib34","doi-asserted-by":"crossref","unstructured":"Irvine DA, Zhang B, Allan EK, et al. Combination of the hedgehog pathway inhibitor LDE225 and nilotinib eliminates chronic myeloid leukemia stem and progenitor cells [abstract]. American Society of Hematology meeting. December 5-8, 2009; New Orleans, LA.","DOI":"10.1182\/blood.V114.22.1428.1428"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib35","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib36","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1158\/0008-5472.CAN-05-0972","article-title":"Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR\/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds","volume":"65","author":"Aichberger","year":"2005","journal-title":"Cancer Res."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","article-title":"ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms","volume":"140","author":"Kuroda","year":"2007","journal-title":"Br J Haematol."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib39","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.cdd.4402168","article-title":"Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia","volume":"14","author":"Kuroda","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib40","first-page":"4267","article-title":"BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells","volume":"9","author":"Tauchi","year":"2003","journal-title":"Clin Cancer Res."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib41","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","article-title":"Regulation of survivin expression through bcr-abl\/MAPK cascade: targeting survivin overcomes imatinib resistance and increases Imatinib sensitivity in Imatinib responsive CML cells","volume":"107","author":"Carter","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib42","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/1535-7163.MCT-09-0386","article-title":"Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells","volume":"8","author":"Mak","year":"2009","journal-title":"Mol Cancer Ther."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib43","article-title":"Inhibition of Bcl-2\/Bcl-XL promotes apoptosis in blast crisis CML including quiescent primitive progenitor cells regardless of cellular responses to tyrosine kinase inhibitors","author":"Mak","year":"2009","journal-title":"American Society of Hematology meeting"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib44","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","article-title":"BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors","volume":"111","author":"Copland","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib45","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib46","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nm0508-494","article-title":"Bedside to bench: interfering with leukemic stem cells","volume":"14","author":"Krause","year":"2008","journal-title":"Nat Med."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib48","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib49","doi-asserted-by":"crossref","unstructured":"Guilhot F, Preudhomme C, Guilhot J, et al. Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with Imatinib (IM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18 months of part 1 of the spirit phase III randomized trial of the French CML Group (FI LMC) [abstract]. American Society of Hematology meeting. December 5-8, 2009; New Orleans, LA.","DOI":"10.1182\/blood.V114.22.340.340"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib50","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05606.x","article-title":"Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors","volume":"130","author":"Angstreich","year":"2005","journal-title":"Br J Haematol."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib52","doi-asserted-by":"crossref","first-page":"28504","DOI":"10.1074\/jbc.M204851200","article-title":"Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis","volume":"277","author":"Leaman","year":"2002","journal-title":"J Biol Chem."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib53","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.06.006_bib54","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/1078-0432.CCR-05-0429","article-title":"Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate","volume":"12","author":"Jorgensen","year":"2006","journal-title":"Clin Cancer Res."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib55","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","article-title":"K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib56","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm1489","article-title":"Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells","volume":"12","author":"Krause","year":"2006","journal-title":"Nat Med."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces CML cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Jin","year":"2008","journal-title":"Mol Cancer Ther."},{"key":"10.1053\/j.seminhematol.2010.06.006_bib58","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2008.06.006","article-title":"Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression","volume":"134","author":"Godar","year":"2008","journal-title":"Cell"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:07Z","timestamp":1758522067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0037196310000806"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Elusive Chronic Myeloid Leukemia Stem Cell: Does It Matter and How Do We Eliminate It?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}